TARRYTOWN, N.Y. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that Progenics is submitting a New Drug Application (NDA) today for marketing approval to the U.S. Food and Drug Administration (FDA) for the subcutaneous formulation of methylnaltrexone for the treatment of opioid-induced constipation (OIC) in patients receiving palliative care. Methylnaltrexone is a peripherally acting opioid-receptor antagonist that is designed to treat OIC without interfering with pain relief.
